Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tidal Therapeutics

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children

Dupixent is now the first and only targeted medicine in the EU for this patient population

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis

Atopic dermatitis affects over 26 million people in the US alone

- PMLiVE

Sanofi to cut US insulin prices by up to 78% in January 2024

The announcement follows similar moves by Novo Nordisk and Eli Lilly earlier this month

- PMLiVE

Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

- PMLiVE

Sanofi to acquire Provention Bio in deal worth $2.9bn

The merger includes recently-approved type 1 diabetes prevention therapy Tzield

Medscape Oncology: Delivering Impact at ASH

You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...

Medscape Education Global

- PMLiVE

BioNTech and Weizmann Institute to collaborate at company’s new mRNA centre in Israel

The research facility is expected to start operations by the end of the year

- PMLiVE

Rare Disease Day 2023 – raising awareness around the world

Around one in 17 people will be affected by a rare disease at some point in their lives

- PMLiVE

Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib

It is estimated that there are over 130,000 people living with the condition in the UK alone

- PMLiVE

Sanofi and Sobi’s once-weekly haemophilia A treatment approved by FDA

Current factor VIII therapies usually require patients to receive treatment every two days

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants

RSV is the most common cause of infant respiratory infections, including pneumonia

- PMLiVE

Moderna and Life Edit partner to accelerate gene editing therapies

The companies will jointly develop in vivo mRNA therapies for hard-to-treat diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links